Centessa Pharmaceuticals plc (CNTA)
Jun 24, 2026 - CNTA was delisted (reason: acquired by LLY)
40.50
+0.32 (0.80%)
Inactive · Last trade price on Jun 23, 2026

Centessa Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2020
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '20
Revenue
015-6.85--
Revenue Growth
------
Gross Profit
015-6.85--
Operating Income
-256.69-207.69-201.06-171.28-212.26-10.44
Net Income
-250.64-197.53-235.76-151.09-216.21-10.66
Earnings Per Share
-1.79-1.46-2.06-1.57-2.31-0.80
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2020
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '20
Cash & Investments
276.59294.58482.18256.55393.645
Total Debt
117.81117.67117.2384.5969.84.17
Net Cash (Debt)
158.78176.91364.95171.96323.840.83
Net Cash Growth
-5.00%-51.52%112.23%-46.90%38823.56%-
Net Cash Per Share
1.131.303.191.793.470.21

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2020
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '20
Operating Cash Flow
-208.8-193.82-142.06-160.34-200.55-10.63
Capital Expenditures
-0.31-0.37-0.03-0.17-1.14-
Free Cash Flow
-209.1-194.19-142.09-160.51-201.68-10.63
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2020
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '20
Gross Margin
-100.00%-100.00%--
Operating Margin
--1384.61%--2499.39%--
Pretax Margin
--1304.75%--2570.28%--
Profit Margin
--1316.88%--2204.65%--
FCF Margin
--1294.59%--2342.20%--

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-248.81-111.71--